Breast Cancer

New ASCO Guidelines Offer a Practice-Changing Approach for PIK3CA/AKT1/PTEN Metastatic Breast Cancer

When to Order Immunohistochemistry Testing: With Tailored Therapies for HER2-Positive Cancers, IHC is More Relevant for More Patients

Oncologists Weigh in on Optimal Use of CDK 4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer

NATALEE Trial Supports Use of Kisqali with HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence

For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Enfortumab Vedotin (Padcev) Shows Some Anti-Tumor Activity

woman walking outside

HER2-Low, A New Classification Of Breast Cancer, Expands The Use Of Enhertu For Metastatic Patients

Elacestrant (Orserdu) Is Effective For A Stubborn Form of Metastatic Breast Cancer

woman with long hair on beach

Drug Enhertu Targets New Category of Her2-Low Metastatic Breast Cancer Patients

Nearly 50% Skip Prescribed Breast Cancer Meds — Physicians Should Focus on Education & Cutting Costs

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

An Evidence-Based Approach to Discussing Clinical Trials With Your Patients

ASCO: Updated Guidelines on Biomarkers for Early-Stage Breast Cancer

Living

ASCO: New Study Provides Hope For Patients With HER2 ‘Low’ Breast Cancer

A new study presented at ASCO on the drug ENHERTU gives hope to women with metastatic HER2 “low” breast cancer. HER2 “low” may become a new...